GLPG (Galapagos) Kelajakdagi narxning foydaga nisbati

Galapagos (GLPG) kompaniyasining rasmiy ramzlari

Global mojarolar xalqaro dori-darmon sinovlariga to'sqinlik qilmoqda va komponentlar logistikasini buzmoqda. GURU.Markets platformasida Galapagos NV uchun kelajakdagi P/E ko'rsatkichi bozor muvozanatini izlashni aks ettiradi va ushbu parametr 0.00 qiymatiga yetmoqda. Galapagos NV istiqbollari CAR-T terapiyasi va Gilead bilan ittifoqqa bog'liq, shu bilan birga, ulkan naqd pul rezervlari tadqiqot va ishlanmalar (R&D) xarajatlarini hamda moliyaviy xatarlarni to'liq qoplaydi.

glpg.com - GLPG Kapitalizatsiyaning kelajakdagi foydaga nisbati (davr: 04.07.2022 - 08.05.2026)

glpg.com (GLPG) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari

- joriy narx va aksiyalarning prognoz qilingan qiymati:
- biznesning bozor baholash ko'rsatkichlari:
Fundamental baholash:Galapagos N.V.
Galapagos NV brendining mahsuloti

Professional kapital Galapagos NV kompaniyasini kelgusidagi daromadlilik prizmasidan baholaydi, bunda geosiyosat tufayli global klinik sinovlarning buzilish xavfi foyda prognozlariga bevosita ta'sir ko'rsatadi. Kompaniyaning kutilayotgan P/E koeffitsiyentidagi 0.00 miqdoridagi joriy o'zgarish, kelgusi sof foydaga nisbatan aksiya narxi bo'yicha bozor konsensusini aks ettiradi va bu investorlarga logistik beqarorlik sharoitida aktivning premium darajasini aniqlash imkonini beradi.

Raqobatchilar tahlili

Kelajakdagi narxning foydaga nisbati haleon.com (HLN)|KVUE (Kenvue Health) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Prognoz qilingan narx-foyda nisbati|LGND: Prognoz qilingan narxning foydaga nisbati|Amneal - Kapitalizatsiyaning kelajakdagi foydaga nisbati|PRGO: Forvard P/E multiplikatori|Alvotech Corp - Kelajakdagi narx-foyda multiplikatori|LQDA (Liquidia Corp) - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati anipharmaceuticals.com ANIP|Kelajakdagi narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|Forvard P/E multiplikatori ARS Corp SPRY|Theravance Biopharma - Forvard P/E multiplikatori|Forvard narx-foyda multiplikatori Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Kelajakdagi narxning foydaga nisbati|Prognoz qilingan narxning foydaga nisbati Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati SXTC (China SXT Pharmaceuticals)|Forvard P/E multiplikatori EPRX|Forvard P/E multiplikatori bioharvest.com (BHST)|Kelajakdagi narxning foydaga nisbati Invizyne Technologies EXOZ|ORMP: Narxning kelajakdagi foydaga nisbati|ENTX: Prognoz qilingan narxning foydaga nisbati|HYFT: Kelajakdagi narxning foydaga nisbati|ABVC BioPharma Inc. (ABVC) - Kelajakdagi narxning foydaga nisbati|cumberlandpharma.com (CPIX) - Forvard P/E multiplikatori|QNTM (Quantum BioPharma) - Forvard P/E multiplikatori|FGEN: Kelajakdagi narx-foyda multiplikatori|Forvard P/E multiplikatori TELO|Forvard P/E multiplikatori Rani Therapeutics Holdings (RANI)|Forvard P/E multiplikatori SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Prognoz qilingan narx-foyda nisbati|LEXX - Kelajakdagi narxning foydaga nisbati|PULM (Pulmatrix) - Narxning kelajakdagi foydaga nisbati|Pheton Holdings Ltd (PTHL) - Kelajakdagi narxning foydaga nisbati|Aptorum - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati LYRA|Prognoz qilingan narxning foydaga nisbati Impact BioMedical Inc (IBO)|Forvard P/E multiplikatori TNFA|YCBD: Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati PainReform PRFX|altamiratherapeutics.com (CYTO) - Prognoz qilingan narx-foyda nisbati|LIPO: Prognoz qilingan narxning foydaga nisbati|OPTN (optinose.com) - Narxning kelajakdagi foydaga nisbati|PIRS: Forvard P/E multiplikatori|PROC - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|PTPI (Petros Pharma) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati QLI|Forvard P/E multiplikatori SLRN|Kapitalizatsiyaning kelajakdagi foydaga nisbati TFFP